Heart Health

This news channel includes content on cardiovascular disease prevention, cardiac risk stratification, diagnosis, screening programs, and management of major risk factors that include diabetes, hypertension, diet, life style, cholesterol, obesity, ethnicity and socio-economic disparities.
 

RSS icon
Researchers have found that an unexpected combination—artificial intelligence (AI) and a 3D body scanner—can evaluate a person’s metabolic health and identify significant risks of cardiovascular disease, diabetes and other adverse outcomes. In fact, the technique may prove to be more accurate than knowing a person’s body mass index (BMI) or waist-to-hip ratio.

Better than BMI? 3D body scanner uses AI to measure metabolic health

Mayo Clinic specialists have developed a new way to identify risks of cardiovascular disease, diabetes and other adverse outcomes.

Thumbnail

Diets high in plant-based fats may help adults live longer with healthier hearts

Even just replacing 5% of your daily fat from animal sources with plant-based fats was found to make a significant impact.

Tandem Diabetes Care is recalling a recent update of the mobile app for its t:slim X2 insulin pump due to repeated software issues that may cause the pump to shut down unexpectedly. The FDA has said this is a Class I recall.

Patient risks persist for insulin pump caught in Class I recall

A software update for the pump's mobile app was expected to fix ongoing battery issues, but the problem remains. 

Huxley Medical, an Atlanta-based medical device company, has secured U.S. Food and Drug Administration (FDA) clearance for its new Sansa device, a chest-worn patch designed to help diagnose sleep apnea in addition to tracking patient data with electrocardiograms (ECGs) a variety of sensors.

FDA clears chest-worn patch for simultaneous ECG, sleep apnea monitoring

The new device from Huxley Medical offers care teams a way to monitor patients for signs of sleep apnea while also keeping a close eye on their heart health. 

Thumbnail

Medtronic and Abbott join forces to develop new diabetes tech

Medtronic and Abbott are often seen as rivals in a competitive marketplace, but the two companies are collaborating with a simple goal in mind: improving patient access to high-quality CGM devices. 

Abbott’s FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system

Abbott says some FreeStyle Libre 3 sensors need replacement—patients should discontinue use

The new medical device correction only includes a select number of devices. Abbott said they produce inaccurate readings, putting patient health at risk. 

tirzepatide injections Zepbound Eli Lilly

Tirzepatide benefits obese HFpEF patients with and without type 2 diabetes

The diabetes drug, sold by Eli Lilly and Company under the brand names Zepbound and Mounjaro, was associated with better outcomes, improved symptoms and more significant weight loss than a placebo.

doctor with overweight patient who may be treated with TAVR or surgery

Bariatric surgery improves heart health, survival in obese patients with obstructive sleep apnea

A team of Cleveland Clinic specialists tracked data from more than 13,000 patients, focusing on all-cause mortality and long-term cardiovascular outcomes.

Displaying 65 - 72 of 990
Design by Adaptive Theme